Wistar scientists developed a chimeric molecule combining an Aurora kinase A (AURKA) inhibitor with an HSP90-targeting molecule, concentrating treatment in tumor cells up to 10 times higher than the inhibitor alone in mice models of head and neck, lung, and melanoma cancers.1
The new molecule stopped cancer cell division and replication in lab tests across multiple cancer types and was well-tolerated in preclinical animal models with no significant toxicity.1
Combining the chimeric molecule with a WEE1 inhibitor enhanced tumor growth control in mice, suggesting broader applications for various cancers.1
KRAS inhibitors in mice with mutant KRAS pancreatic ductal adenocarcinoma (PDAC) tumors showed deeper tumor regressions when T cells were present, highlighting immune system partnership.2
A next-generation BRAF inhibitor, mosperafenib, was characterized as a 'paradox-breaker' in preclinical colorectal cancer studies, addressing resistance issues.5
Sources:
1. https://medicalxpress.com/news/2026-02-dual-action-molecule-cancer-treatment.html
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC12962316/
5. https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-25-0562/771896/Mosperafenib-a-Novel-Paradox-Breaker-BRAF